Slingshot members are tracking this event:

TEVA Launches Generic Ortho Tri-Cyclen Lo (norgestimate/ethinyl estradiol) tablets in the United States

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

TEVA.TA Community voting in process

Additional Information

Additional Relevant Details Ortho Tri-Cyclen Lo (norgestimate/ethinyl estradiol) tablets, marketed by Janssen Pharmaceuticals, Inc., had annual sales of approximately $488 million in the United States, according to IMS data as of October 2015. Tri-Lo-Sprintec is indicated for use by females of reproductive potential to prevent pregnancy. Tri-Lo-Sprintec does not protect against HIV infection (AIDS) and other sexually transmitted diseases.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 05, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Norgestimate, Ethinyl Estradiol, Ortho Tri-cyclen Lo, Generic, Contraceptive